Article
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
Cancer discovery - 1 Mar 2017
Toy Weiyi, Weir Hazel, Razavi Pedram, Lawson Mandy, Goeppert Anne U, Mazzola Anne Marie, Smith Aaron, Wilson Joanne, Morrow Christopher, Wong Wai Lin, De Stanchina Elisa, Carlson Kathryn E, Martin Teresa S, Uddin Sharmeen, Li Zhiqiang, Fanning Sean, Katzenellenbogen John A, Greene Geoffrey, Baselga José, Chandarlapaty Sarat
Abstract excerpt
Recent studies have identified somatic ESR1 mutations in patients with metastatic breast cancer and found some of them to promote estrogen-independent activation of the receptor. The degree to which all recurrent mutants can drive estrogen-independent activities and reduced sensitivity to ER antagonists like fulvestrant is not established. In this report, we characterize the spectrum of ESR1 mutations from more...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.